Member Info for matarakz

86% up now. Becoming bullish imho

Only few companies are good in AIM but Novacyte is the excellent in AIM so far imho
Mammoth revenue
Fully funded
No dilution
Partnering with multibillion companies
Excellent distributorship in more than 100 countries
IMHO

Tristel has a market cap of £230 million with less than £30 million revenue per annum and Novacyt has potential of having a revenue between £500 million to £1 billion and yet
our market cap is still very small imho. At least it should be £15. Gla

Soon we may hit £5 by lunch time imho. Gla

I have a feeling we may hit £5 today imho. Patience is the key to success again

Hopefully profit takers - gone now. We are heading north now imho.

I dip my top already. This is excellent company
No dilution
Fully funded
Big profit and revenue and should be a billion dollar company imho.

To all investors, this is not AIM anymore imho. It is acting like FTSE250. Good for all investors imho.Gla

A mammoth Rns . Gla

France is moving forward now. Gla

£20-£30 imho

With this excellent Rns, no one want to sell now till £15-20 for me imho. Gla

Praise God Alleluia!

https://www.telegraph.co.uk/news/2020/04/26/game-changing-oxford-antibody-test-claims-overblown/
This is the genuine news. Daily mail news was a fake news

https://pbs.twimg.com/media/EWhhh44XgAAHgyj?format=jpg&name=large

By Patrick , again Patience is the key to Success!

Very strong in the last few mins! Gl on Monday

The problem with antibody test is it is unreliable. If you build up immunity against Covid 19 , it will be only temporary and there are a lot of reported reinfection with covid 19 imho.

Stampede again imho in the last 30 mins. Gla for the superduper RNS on Monday i guess.

The most import thing is our different products are being promoted now to more than 100 countries imho. A lot of interests now from different countries imho.Gl

From CEO



"In addition, we believe interest in our COVID-19 test will have a positive, long-term impact on Novacyt as new customers look to purchase our broader product range. We are already seeing an increased demand for our B2B capabilities as customers look to utilise our molecular design and development capabilities